ReviewFrontiers in physiology2021
The Microbiome in Autoimmune Liver Diseases: Metagenomic and Metabolomic Changes.
Review in Frontiers in physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Bile acids as a "new hormone" in aging-related liver disease.Life medicine · 2026Review
- Underestimated and Overlooked Factors in PBC Progression: Bacterial and Fungal Infections.International journal of molecular sciences · 2026Review
- Research progress on the role of gut microbiota dysbiosis in the pathogenesis of immune-mediated liver diseases.Frontiers in immunology · 2026Review
- Advancing the management of primary biliary cholangitis: From pathogenesis to emerging therapies.World journal of clinical cases · 2025Review
- Multi-omics analysis reveals gut microbiota-metabolite interactions and their association with liver function in autoimmune overlap syndrome.World journal of gastroenterology · 2025Article
- Effects of Probiotics on Liver Diseases: Current In Vitro and In Vivo Studies.Probiotics and antimicrobial proteins · 2025Review
- Interacting roles of gut microbiota and T cells in the development of autoimmune hepatitis.Frontiers in immunology · 2025Review
- Innate immunity of bile and cholangiocytes in primary biliary cholangitis.Frontiers in immunology · 2025Review
- Genetically predicted immune cells mediate the association between gut microbiota and autoimmune liver diseases.Frontiers in microbiology · 2024Article
- Alterations in gut microbiota and metabolite profiles in patients with infantile cholestasis.BMC microbiology · 2023Article
- Causal effects of gut microbiome on autoimmune liver disease: a two-sample Mendelian randomization study.BMC medical genomics · 2023Article
- Risk Stratification in Primary Biliary Cholangitis.Journal of clinical medicine · 2023Review
- Differences in Gut Microbiome Profile between Healthy Children and Children with Inflammatory Bowel Disease and/or Autoimmune Liver Disease: A Case-Control Study.Pathogens (Basel, Switzerland) · 2023Article
- High prevalence of lower limb atherosclerosis is linked with the gut-liver axis in patients with primary biliary cholangitis.Liver international : official journal of the International Association for the Study of the Liver · 2023Article
- Research progress on the relationship between intestinal microecology and intestinal bowel disease.Animal models and experimental medicine · 2022Review
- Role of intestinal flora in primary sclerosing cholangitis and its potential therapeutic value.World journal of gastroenterology · 2022Review
- Serum metabolic profiling of targeted bile acids reveals potentially novel biomarkers for primary biliary cholangitis and autoimmune hepatitis.World journal of gastroenterology · 2022Article
- HLA, gut microbiome and hepatic autoimmunity.Frontiers in immunology · 2022Review
- Inflammatory pathways and cholangiocarcinoma risk mechanisms and prevention.Advances in cancer research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies have identified the critical role of microbiota in the pathophysiology of autoimmune liver diseases (AILDs), including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). Metagenomic studies reveal significant decrease of gut bacterial diversity in AILDs. Although profiles of metagenomic vary widely,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.